Compare PNTG & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PNTG | PCRX |
|---|---|---|
| Founded | 2019 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | N/A | 2011 |
| Metric | PNTG | PCRX |
|---|---|---|
| Price | $30.38 | $20.94 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 6 |
| Target Price | ★ $36.50 | $35.33 |
| AVG Volume (30 Days) | 334.2K | ★ 1.0M |
| Earning Date | 02-26-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 10.47 | N/A |
| EPS | ★ 0.75 | 0.47 |
| Revenue | ★ $847,274,000.00 | $716,791,000.00 |
| Revenue This Year | $36.42 | $6.21 |
| Revenue Next Year | $23.99 | $8.26 |
| P/E Ratio | ★ $40.37 | $44.56 |
| Revenue Growth | ★ 29.89 | 3.14 |
| 52 Week Low | $21.18 | $18.80 |
| 52 Week High | $31.94 | $27.64 |
| Indicator | PNTG | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 58.41 | 42.88 |
| Support Level | $26.67 | $20.24 |
| Resistance Level | $30.53 | $21.60 |
| Average True Range (ATR) | 1.40 | 0.83 |
| MACD | 0.08 | 0.15 |
| Stochastic Oscillator | 67.68 | 70.00 |
Pennant Group Inc is engaged in providing healthcare services to patients of all ages, including the growing senior population, in the United States. It operates in multiple lines of business including home health, hospice, and senior living which includes the company's assisted living, independent living, and memory care communities across Arizona, California, Colorado, Idaho, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin, and Wyoming. The company generates majority of its revenue from home health and hospice services segment, which includes its home health, hospice and home care businesses.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.